Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
-
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
-
Ligand to Participate in November Investor Conferences
-
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
-
Ligand to Host Investor Day on December 9, 2025
-
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
-
Ligand to Participate in September Investor Conferences
-
Ligand Announces Closing of Convertible Senior Notes Offering
-
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
-
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030